Senseye leverages brain-based diagnostics and computer vision technology to transform the diagnostic process for PTSD, anxiety, depression, and addiction into an objective process. The diagnostic runs on smartphones from any location—including telehealth settings—with no specialized equipment or upfront capital investment needed, creating significant accessibility and scalability advantages in mental health diagnostics.
Cyborg Score Rationale
Senseye's platform has been used by over 3,000 patients and is advancing toward FDA approval for PTSD and major depressive disorder, with commercial deployments in healthcare and pharma applications. The company has raised $29.81M and holds 9 patents. However, significant regulatory hurdles remain and market adoption is still early-stage.
Top Insights
Senseye targets massive TAM: mental health diagnostics remain heavily subjective; company delivers first objective, smartphone-enabled assessment for PTSD, depression, and anxiety—accessible at point-of-care and telehealth-suitable
Strong government validation: U.S. Air Force backing Phase II development for traumatic brain injury detection, aligns with military readiness imperatives, and DOD/civilian health system partnerships indicate institutional credibility
Patent-protected dual advantage: proprietary deep learning and signal extraction plus ocular biomarker IP; platform already deployed across 3,000+ patients with FDA approval pathway for multiple indications
Capital-efficient, smartphone-native model: no specialized equipment dependency reduces provider friction and deployment cost, creating high-margin SaaS potential in mental health, pharma trials, and occupational health screening
Named Competitors
BrainCheck — Cognitive and neurological assessment platform
Monument Therapeutics — Neuroscience company developing digital biomarkers for CNS disorders
Recent Developments
(2024 Q1) Senseye operating platform with over 3,000 patient deployments, advancing FDA approval milestones for PTSD and major depressive disorder
(Ongoing) U.S. Air Force Phase II contract partnership for traumatic brain injury diagnostic development with AFRL and medical wing collaboration
(Ongoing) Commercial deployment expanding in healthcare and pharmaceutical clinical trial recruitment applications
Open the full interactive Senseye, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.